Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06407232 · ClinicalTrials.gov registry record · Phase 3
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
A Phase 3 study of Cytomegalovirus Infections and Kidney Transplant Infection, sponsored by University of Wisconsin, Madison.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT06407232: Recruiting Phase 3 study of Cytomegalovirus Infections and Kidney Transplant Infection, sponsored by University of Wisconsin, Madison.
NCT06407232 is a Phase 3 study of Cytomegalovirus Infections and Kidney Transplant Infection that is actively recruiting participants, run by University of Wisconsin, Madison. The registered enrollment target is 90 participants, below the 199-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06407232, a Phase 3 study of Cytomegalovirus Infections and Kidney Transplant Infection, is actively recruiting participants, sponsored by University of Wisconsin, Madison.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.
Primary Outcome
To test the hypothesis that letermovir will be associated with reduced incidence of recurrent viremia, recurrence will be measured defined as incidence of any cytomegalovirus replication greater than 1000 IU/mL requiring treatment after withdrawal of secondary prophylaxis.
Conditions Studied
Interventions
- DRUG Letermovir
Study Locations (1)
Wisconsin
- UW Hospital and Clinics - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-08-08 |
| Est. Completion | 2026-09 |
| Phase | Phase 3 |
What NCT06407232 shows while recruiting
NCT06407232 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 199-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (55% lower).
The record links to 3 conditions, with Cytomegalovirus Infections appearing as the primary indexed condition, and to 1 intervention - of which Letermovir is the first listed.
NCT06407232 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06407232 about?
NCT06407232 is a clinical study titled "Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients". This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.
What is the current status of trial NCT06407232?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2024-08-08. Estimated completion is 2026-09.
What conditions does trial NCT06407232 study?
This clinical trial studies the following conditions: Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant.
What interventions are being tested in trial NCT06407232?
The interventions under investigation include: Letermovir (DRUG).
Who is sponsoring clinical trial NCT06407232?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06407232 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytomegalovirus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06407232's enrollment target sits among peer trials
90 10th of 24 higher than 14 of 24 other Cytomegalovirus Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cytomegalovirus Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients
COMPLETED · Phase 3
-
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
COMPLETED · Phase 3
-
A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.
COMPLETED · Phase 3
-
The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients
COMPLETED · Phase 3
-
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
RECRUITING · Phase 4
-
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI